No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.

Abstract excerpt

BRAF is the main effector of KRAS in the RAS-RAF-MAPK axis, a signaling pathway downstream of EGFR. The activation of this cascade is an important pathway in cancer development and is considered a key pathway for therapeutic molecules. Recent studies in metastatic colorectal cancer found that an oncogenic activation of BRAF by a point mutation in exon 15 (V600E) could bypass the EGFR-initiated signaling cascade...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alleles
• Share to DNA Mutational Analysis